IBA Molecular is a worldwide leader in radiopharmaceuticals, providing diagnostic and therapeutic products of the highest quality with outstanding service and reliability. We are committed to assisting advanced diagnostic imaging programs with radioisotopes for PET and SPECT modalities and targeting unmet medical needs in oncology, cardiology and neurology as part of our goal to assist healthcare programs in delivering improved patient care and outcomes.
Our worldwide manufacturing and distribution network is comprised of 13 CGMP-compliant radiopharmacies in the United States and 36 radioisotope production facilities across Europe and Asia. Our employees, with exceptional backgrounds, expertise and commitment, are the backbone of our business. Working in IBA Molecular's state-of-the-art regulatory-compliant facilities, they are developing and producing our products under the strictest standards.
IBA Molecular is jointly owned by SK Capital Partners (US) and IBA SA (Belgium). In April 2012, IBA SA sold a majority interest in IBA Molecular to SK Capital to form a stand-alone molecular imaging company.
To help us better serve you, please select your region: